middle.news
Chimeric Therapeutics Advances $2.5M on R&D Tax Incentive to Fuel Trials
12:41pm on Tuesday 10th of June, 2025 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Advances $2.5M on R&D Tax Incentive to Fuel Trials
12:41pm on Tuesday 10th of June, 2025 AEST
Key Points
Secured $2.5 million advance from Endpoints Capital
Funding backed by anticipated FY25 R&D Tax Incentive refund
Supports clinical trial pipeline and general working capital
Follows recent $6.6 million placement and $1 million entitlement offer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE